Rabbit Anti-Human VEGFR-2/KDR
Slide this table
Cat-Nr. | 102-PA18 |
Size | 200 µg |
Price | 305 € |
Category | Polyclonal Antibody |
Clone Nr. | Rabbit IgG |
Species Reactivity | Human |
Formulation | lyophilized |
Buffer | PBS |
Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
Preparation | Produced from sera of rabbits immunized with highly pure recombinant human soluble extracellular domain of KDR (110 kDa) as the immunizing antigen. Anti-human VEGFR-2/KDR was purified by affinity chromatography with immobilized protein A. The antibody is identical with the former described antibody r212 (see Lit.) |
Antigen | Recombinant human KDR (D1-7) (RT #S01-001) |
Application | WB, E, IP |
Synonyms | vascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; VEGFR2; kinase insert domain protein receptor |
Description | VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. |
Uniprot ID | P35968 |
Protein RefSeq | NP_002244.1 |
mRNA RefSeq | NM_002253.2 |
Figures
![](/fileadmin/user_upload/products/VEGFR-2_KDR/102-PA18_IHC_zusammen.jpg)
IHC with cryo sections of human spleen.
The experiment was performed by Prof. Dr. Birte Steiniger, Institute of Anatomy and Cell Biology, University Marburg, Germany
![](/fileadmin/user_upload/products/VEGFR-2_KDR/102-PA18_WB.jpg)
Western Blot Analysis of anti-human VEGFR-2/KDR. Samples were loaded in 10% SDS-polyacrylamide gel under reducing conditions.
![](/fileadmin/user_upload/products/VEGFR-2_KDR/102-PA18_FC_HUVEC.jpg)
FACS analysis with primary human umbilical vein endothelial cells (HUVEC).
![](/fileadmin/user_upload/products/VEGFR-2_KDR/102-PA18_FC.jpg)
FACS analysis with primary human dermal lymphatic endothelial cells (HDLEC).
Reference
- The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. S. Dedieu et al., BMC Med. 2010; 8: 19.
All prices plus VAT + possible delivery charges